These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34592434)

  • 1. Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
    Price S; Bender SG; Yahn R; Till NA; Varady S; LaLonde RL
    Bioorg Med Chem Lett; 2021 Nov; 52():128383. PubMed ID: 34592434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
    Peng J; Sengupta S; Jordan VC
    Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
    Park WC; Jordan VC
    Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.
    Fan P; Craig Jordan V
    Steroids; 2014 Nov; 90():44-52. PubMed ID: 24930824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
    Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
    Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen to raloxifene and beyond.
    O'Regan RM; Jordan VC
    Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
    Terakawa N
    Oncology; 2000; 59 Suppl 1():3-4. PubMed ID: 11096349
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
    Gajdos C; Jordan VC
    Clin Breast Cancer; 2002 Jan; 2(4):272-81. PubMed ID: 11899358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
    Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
    J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
    Eisen SF; Brown HA
    Mol Pharmacol; 2002 Oct; 62(4):911-20. PubMed ID: 12237338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.
    Cerrato F; Fernández-Suárez ME; Alonso R; Alonso M; Vázquez C; Pastor O; Mata P; Lasunción MA; Gómez-Coronado D
    Br J Pharmacol; 2015 Mar; 172(5):1379-94. PubMed ID: 25395200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in the prevention of breast cancer: concept to reality.
    Jordan VC
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
    Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene.
    Miki Y; Suzuki T; Nagasaki S; Hata S; Akahira J; Sasano H
    J Steroid Biochem Mol Biol; 2009 Feb; 113(3-5):281-9. PubMed ID: 19429434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune activity of selective estrogen receptor modulators is gene and macrophage subtype-specific yet converges on Il1b downregulation.
    Sfogliarini C; Pepe G; Cesta CM; Allegretti M; Locati M; Vegeto E
    Biomed Pharmacother; 2023 Sep; 165():115008. PubMed ID: 37442065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    Jordan VC; O'Malley BW
    J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.
    McDonnell DP; Wardell SE; Norris JD
    J Med Chem; 2015 Jun; 58(12):4883-7. PubMed ID: 26039356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting in the estrogen receptor hormonal pathway.
    Katzenellenbogen BS; Frasor J
    Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
    Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
    ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.